Phase 3 Multiple Sclerosis Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You are between 40 and 70 years old (inclusive)
- You have been diagnosed with relapsing multiple sclerosis (RMS) based on the 2017 McDonald diagnostic guidelines
- You are currently being treated with ocrelizumab (a common MS medication) at the standard dose as part of your regular care
- Your MS symptoms have been stable for at least the past 30 days
- Your doctor believes, or you prefer, that switching to the study drug (remibrutinib) would be appropriate for you
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have been diagnosed with primary progressive multiple sclerosis (PPMS) according to the 2017 McDonald criteria
- You have a significant history of other brain, nervous system, or neurological conditions
- You have previously been diagnosed with a serious brain infection called Progressive Multifocal Leukoencephalopathy (PML), or you currently have symptoms that might suggest it (confirm with trial site)
- You currently have an active and serious infection, such as a bacterial, viral, parasitic, or fungal infection
- You have an active or ongoing immune system disease other than MS
- You have a serious heart condition or significant abnormalities shown on a heart tracing (ECG) test
- You are unable to have MRI scans
- You have previously had a life-threatening reaction to an ocrelizumab infusion or injection
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-888-669-6682
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Annualized rate of new or enlarging T2 lesions_Core Part
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.